Anti-IL-5 antibodies are used in diseases such as eosinophilic asthma, eosinophilic oesophagitis, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis (EGPA).340 Mepolizumab and reslizumab act against IL-5, and benralizumab targets IL-5R. This evidence concerns the gene IL5 and hypereosinophilic syndrome.